Mark Chao

Mark Chao

Oprichter bij FORTY SEVEN, INC.
Health Technology
Consumer Services
Finance

Profiel

Mark Chao is the founder of Hepatx Corp.
(2015), Forty Seven LLC (2014), and TenSixteen Bio, Inc. (2021).
Dr. Chao is also the founder of Gilead Sciences, Inc. Dr. Chao is currently an Advisor at Bioverge Funds Management LLC, a Venture Partner at Foresite Labs LLC, a Scientific Advisory Board Member at IconOVir Bio, Inc., and a Scientific Advisory Board Member at TigaTx, Inc. Education includes a graduate degree from Stanford University (2011), an undergraduate degree from Case Western Reserve University (2004), and both a graduate degree and a doctorate from Stanford University School of Medicine (2011).

Actieve functies van Mark Chao

BedrijvenFunctieBegin
FORTY SEVEN, INC. Oprichter 01-01-2014
Private Equity Investor 01-01-2021
Consultant / Adviseur 01-12-2021
Consultant / Adviseur 01-05-2020
Consultant / Adviseur -

Eerdere bekende functies van Mark Chao

BedrijvenFunctieEinde
Algemeen Directeur 01-01-2023
GILEAD SCIENCES, INC. Oprichter -
Oprichter -
Ervaring van Mark Chao in detail bekijken

Opleiding van Mark Chao

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

88

Eerstegraads connecties

11

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit11

Health Technology

Consumer Services

Consumer Services

Health Technology

Consumer Services

Finance

Technology Services

Commercial Services

Health Technology

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. Mark Chao